Beyond The New Drug Headlines

Want to continue the discussion? Send me a message.A new psychiatric medication gets approved, social media starts buzzing, and suddenly the question lands in the exam room: “Should I take this?” We want to slow that moment down. A headline about a new mechanism of action is interesting, but it does not answer the real clinical question: where does this treatment fit for the person sitting right in front of us, with their diagnosis, goals, risks, and real life constraints.We walk through a practical, evidence-based way to evaluate new medications for schizophrenia and bipolar disorder, starting with the FDA label. What is it actually approved to treat? Which age group? Is it meant to be used alone or with other meds? From there, we zoom into clinical trials and talk honestly about how controlled study settings differ from community mental health and routine outpatient care where adherence varies, stressors happen, insurance changes, and follow-up is less frequent.We also dig into communication, because many clients now research medications on Google, Reddit, and personal blogs before we finish the visit. We share how to respect that curiosity while clarifying the difference between personal stories and clinical evidence, how to interpret long side-effect lists with real context, and why the teach-back method can make a plan safer and easier to follow. Finally, we focus on tolerability over time and what “success” truly means, not just on a rating scale but in sleep, connection, functioning, and quality of life as defined by the client.Podcast, Newsletter & More https://linktr.ee/Dr.LoriKumarDNP